102 related articles for article (PubMed ID: 17029280)
1. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples.
Wentzensen N; Hampl M; Herkert M; Reichert A; Trunk MJ; Poremba C; Ridder R; von Knebel Doeberitz M
Cancer; 2006 Nov; 107(9):2307-13. PubMed ID: 17029280
[TBL] [Abstract][Full Text] [Related]
2. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
3. An analysis on the combination expression of HPV L1 capsid protein and p16INK4a in cervical lesions.
Huang MZ; Li HB; Nie XM; Wu XY; Jiang XM
Diagn Cytopathol; 2010 Aug; 38(8):573-8. PubMed ID: 19941368
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia.
Saqi A; Pasha TL; McGrath CM; Yu GH; Zhang P; Gupta P
Diagn Cytopathol; 2002 Dec; 27(6):365-70. PubMed ID: 12451568
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of level of expression of p16 (INK4a) in endocervical lesions of uterine cervix].
Popovska S; Betova T; Tomov S; Gorchev G; Dikov T
Akush Ginekol (Sofiia); 2005; 44(5):9-13. PubMed ID: 16313047
[TBL] [Abstract][Full Text] [Related]
6. Performance of p16INK4a ELISA as a primary cervical cancer screening test among a large cohort of HIV-infected women in western Kenya: a 2-year cross-sectional study.
Wu TJ; Smith-McCune K; Reuschenbach M; von Knebel Doeberitz M; Maloba M; Huchko MJ
BMJ Open; 2016 Sep; 6(9):e012547. PubMed ID: 27625065
[TBL] [Abstract][Full Text] [Related]
7. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia.
Wentzensen N; Bergeron C; Cas F; Vinokurova S; von Knebel Doeberitz M
Cancer; 2007 Feb; 111(1):58-66. PubMed ID: 17186505
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of p16INK4a as a diagnostic tool in the triage of Pap smears demonstrating atypical squamous cells of undetermined significance.
Duncan L; Jacob S; Hubbard E
Cancer; 2008 Feb; 114(1):34-48. PubMed ID: 18186493
[TBL] [Abstract][Full Text] [Related]
9. The role of HPV testing in patients with possible high-grade cervical cytology.
Rao A; Pather S; Dalrymple C; Mackie A; Deans R; Carter J
J Obstet Gynaecol Res; 2009 Jun; 35(3):503-6. PubMed ID: 19527390
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study.
Mao C; Balasubramanian A; Yu M; Kiviat N; Ridder R; Reichert A; Herkert M; von Knebel Doeberitz M; Koutsky LA
Int J Cancer; 2007 Jun; 120(11):2435-8. PubMed ID: 17294450
[TBL] [Abstract][Full Text] [Related]
11. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia.
Samarawardana P; Dehn DL; Singh M; Franquemont D; Thompson C; Gaido L; Torkko KC; Homer P; Burke S; Titmus MA; Nayi V; Shroyer KR
Cancer Cytopathol; 2010 Jun; 118(3):146-56. PubMed ID: 20544710
[TBL] [Abstract][Full Text] [Related]
12. p16INK4A expression in cervical premalignant and malignant lesions.
Lambert AP; Anschau F; Schmitt VM
Exp Mol Pathol; 2006 Apr; 80(2):192-6. PubMed ID: 16257403
[TBL] [Abstract][Full Text] [Related]
13. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of HPV test on cell sample from the cervix].
Vintermyr OK; Skar R; Iversen OE; Haugland HK
Tidsskr Nor Laegeforen; 2008 Jan; 128(2):171-3. PubMed ID: 18202727
[TBL] [Abstract][Full Text] [Related]
15. Direct visual inspection of the cervix with Lugol iodine for the detection of premalignant lesions.
El-Shalakany AH; Saeed MM; Abdel-Aal MR; El-Nakeeb AH; Noseirat N; Ayyad SB; El Din ZS
J Low Genit Tract Dis; 2008 Jul; 12(3):193-8. PubMed ID: 18596460
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity of p16 in anal cytology specimens: histologic correlation.
Darvishian F; Stier EA; Soslow RA; Lin O
Cancer; 2006 Feb; 108(1):66-71. PubMed ID: 16404747
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.
Dehn D; Torkko KC; Shroyer KR
Cancer; 2007 Feb; 111(1):1-14. PubMed ID: 17219448
[TBL] [Abstract][Full Text] [Related]
18. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
19. [Cell protein p16INK4a hyperexpression in epithelial malignancies induced by human papillomaviruses].
Volgareva GM; Zavalishina LE; Andreeva IuIu; Shtil' AA; Frank GA
Arkh Patol; 2008; 70(5):57-61. PubMed ID: 19137788
[TBL] [Abstract][Full Text] [Related]
20. Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens.
Oberg TN; Kipp BR; Vrana JA; Bartholet MK; Fales CJ; Garcia R; McDonald AN; Rosas BL; Henry MR; Clayton AC
Diagn Cytopathol; 2010 Aug; 38(8):564-72. PubMed ID: 19937941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
